Cyclacel Announces Clinical Trials For Inflammatory Disease Drug

June 2002
Drug Discovery & Development;Jun2002, Vol. 5 Issue 6, p25
Reports on British-based Cyclacel's plan to investigate in clinical trials the potential use of its lead drug, CYC202, in the treatment of glomerulonephritis (GN), a group of inflammatory diseases of the kidney. Phases of clinical trials completed.


Related Articles

  • Cyclacel Cutting 28 Staffers, Will Focus on Sapacitabine. Moran, Nuala // BioWorld International;9/24/2008, Vol. 13 Issue 39, p1 

    The article reports on the decision of Cyclacel Inc. to reduce its British research and development operations and close its facility in Cambridge as part of a restructuring effort. A total of 28 staff members will leave the company, with 17 in the research base. President Spiro Rombotis says...

  • CYCLACEL REPORTS PROGRESS WITH 2ND GENERATION CDK INHIBITOR.  // Worldwide Biotech;Jul2003, Vol. 15 Issue 7, p4 

    Focuses on the cyclin dependent kinase inhibitors for the genes-to-drugs CYC400 rational drug design program of the biopharmaceutical firm Cyclacel Ltd. in Great Britain.

  • CYCLACEL'S CYC202 INDUCES CANCER CELLS TO COMMIT SUICIDE.  // Worldwide Biotech;Sep2003, Vol. 15 Issue 9, p6 

    Reports on the ability of CYC202 (R-roscovitine), a cyclin-dependent kinases inhibitor product from Cyclacel Ltd., to induce cancer cell suicide or apoptosis in patients receiving the drug.

  • More Trouble Over EU Clinical Trials Rules. O'Donnell, Peter // Applied Clinical Trials;Jan2003, Vol. 12 Issue 1, p21 

    Focuses on the views of health practitioners on the problems associated with the implementation of the European Union directive on clinical trials. Effects of disparate legal regulations on the success of international clinical trials; Details of the protocol amendment procedures and...

  • Study Completion Times.  // Applied Clinical Trials;May2011, Vol. 20 Issue 5, p19 

    The article offers analysis on the study completion times on applied clinical trials of contract research organization or sponsor company of the study in the U.S.

  • Clinical trials: Free help for the asking!  // Hispanic Times Magazine;May/Jun1994, Vol. 15 Issue 3, p34 

    Discusses clinical trials--closely supervised investigations to evaluate new medical treatments for various maladies. How people who have received no relief for their ailment from conventional medicines may want to try a clinical trial; What they usually entail; Requirements involved; How to...

  • How to evaluate the validity and usefulness of published randomized clinical trials. Basskin, Lorne // Formulary;Mar1997, Vol. 32 Issue 3, p279 

    Presents evaluation on the validity and usefulness of published randomized clinical trials. Assessment of validity through cause-and-effect relationship; Four questions in studying usefulness. INSETS: Reasons to review randomized clinical trials (RCTs).;Shortfalls of some information...

  • Clinical drug tests: Women need not apply. Dobie, Maureen // Indianapolis Business Journal;1/22/96, Vol. 16 Issue 45, p15 

    Reports on the exclusion of women in the child-bearing age from clinical drug tests in the United States. Aim to protect eggs in womb; Preference of pharmaceutical companies for male subjects; Requiring of the intake of birth control pills for participating women.

  • Why are randomised controlled trials important? Sibbald, Bonnie; Roland, Martin // BMJ: British Medical Journal (International Edition);01/17/98, Vol. 316 Issue 7126, p201 

    Presents information on the importance of randomised controlled clinical trials. Detailed information on these trials; Details on their importance; Limitations of these trials.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics